J&J’s Commitment To Diversification Through OTCs Rewarded In Q2
This article was originally published in The Tan Sheet
Johnson & Johnson's second-quarter results show the firm's commitment to broader diversification with the 2006 purchase of Pfizer's consumer business was shrewd. The firm's over-the-counter business countered weak performance in the pharma sector
You may also be interested in...
The agency approves Zyrtec (cetirizine HCl) for nonprescription use, one week after it granted McNeil Consumer Healthcare, a subsidiary of Johnson & Johnson, approval to switch the allergy treatment's decongestant combination product, Zyrtec-D (1"The Tan Sheet" Nov. 12, 2007, p. 9). The prescription-strength product will be available OTC in stores starting in late January 2008, J&J says in a Nov. 16 release. The firm received approval for Zyrtec in 5 mg and 10 mg tablets, 5 mg and 10 mg chewable tablets and 1 mg/mL syrup. The once-daily drug is indicated for relieving indoor and outdoor allergy symptoms of sneezing, runny nose and watery eyes for up to 24 hours in adults and children; the drug also relieves itching due to hives, J&J says...
Q4 sales in OTC allergy/cold segment, which includes the Claritin allergy and Afrin nasal congestion lines, grew 5% adjusted while dermatology sector with Bepanthen and Canesten skin care brands grew 3.8%. Adjusted for the impact of foreign exchange and portfolio changes, thouhg, consumer unit’s full-year sales were flat.
Advertising Standards Authority says Green People Co. misled consumers with claims SPF 30 formulas filter out only 1% less UVB rays than SPF 50, trying to draw a negligible difference between the formulas. The claims appeared in a direct mailer and on the brand’s website in July 2019.